LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial

The purpose of this research is to gather information on the safety and effectiveness of spironolactone and chlorthalidone for treatment of high blood pressure in patients with moderate to advanced CKD. Both drugs have been approved by the Food and Drug Administration (FDA) for the treatment of high blood pressure since 1960.

NCT Number	NCT07645300
Lead Sponsor	VA Office of Research and Development Collaborators: Michael E. DeBakey VA Medical Center, VA Salt Lake City Health Care System
Conditions	Hypertension Treated With Antihypertensive Drugs, Chronic Kidney Disease, 3B and 4
Enrollment	160 participants
Start Date	2026-10-01
Primary Completion	2032-03-31 (estimated)
Study Completion	2032-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-12